Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 1(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06968845Phase 2Recruiting

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

Role: lead

NCT05954988Phase 1Completed

A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients

Role: lead

NCT04159831Phase 2Completed

A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions

Role: lead

NCT04233814Phase 1Completed

Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects

Role: lead

All 4 trials loaded